Imagine a world where a single cure costs a million euros, making it impossible for hospitals to afford. This work creates new ways to pay for these medicines, like a subscription service instead of paying per pill. It helps ensure that life-saving drugs reach patients without bankrupting the healthcare system.
High-cost innovative therapies, sometimes exceeding one million Euros per patient, are creating unsustainable financial pressure on healthcare payers. Current payment models cannot handle the budget impact of rare disease cures or large-scale treatments like those for Alzheimer's.
A toolkit for decision-makers to implement new pricing schemes and a set of evidence-based contracting modalities tested in primary and integrated care settings.
If you are a biotech firm dealing with high per-patient prices that can exceed one million Euros — this project developed a toolkit for decision-makers that helps negotiate sustainable payment schemes. This ensures your high-cost therapy remains accessible and affordable for payers.
If you are a public payer dealing with skyrocketing budget impacts from Alzheimer’s treatments — this project developed new contracting modalities to manage financial risk. This prevents system collapse while maintaining patient access to innovation.
If you are a consultancy dealing with a lack of data on R&D costs during reimbursement negotiations — this project developed a map of pricing schemes across different therapeutic areas. This allows you to provide evidence-based pricing strategies to your clients.
The project focuses on creating flexible payment models to handle therapies that can exceed one million Euros per patient. Based on available project data, it aims to balance affordability for payers with incentives for innovation.
Yes, the project aims to formulate schemes that work across different healthcare systems and geographies. It includes a toolkit specifically designed to help decision-makers transfer and generalize these results.
Based on available project data, there is no specific mention of IP or licensing terms; the project focuses on generating evidence and a toolkit for decision-makers.
The project addresses legal barriers and the lack of data infrastructure that currently prevent the use of innovative pricing models.
The project period runs from 2023-01-01 to 2025-12-31, suggesting the final tools and evidence will be available by the end of 2025.
The consortium is heavily academic, with 9 universities and 5 research organizations, indicating a strong theoretical and evidence-based foundation. However, industrial representation is very low at 6% (only 1 industry partner and 1 SME), suggesting the project is more focused on policy and economic modeling than immediate commercial product development.
Contact Università Commerciale Luigi Bocconi in Italy
Contact us to access the HI-PRIX toolkit for healthcare pricing strategy.
